{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-005103","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.703471+00:00","generated_at":"2026-06-27T19:21:37.151513+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M","bullets":["Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).","Over 125 start forms submitted; >95% patient compliance; zero meningococcal infections.","More than 75% of new EMPAVELI starts are switches from competitor Ultomiris."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-005103","json":"https://secwatch.observer/filing/0001193125-22-005103.json","markdown":"https://secwatch.observer/filing/0001193125-22-005103.md","text":"https://secwatch.observer/filing/0001193125-22-005103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/0001193125-22-005103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/d232021d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:21:37.151513+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}